Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Expedia Acquires Travelocity in $280 Million Deal

Consolidation in the online booking community continues.

Re/code

Expedia has acquired online travel agency Travelocity from technology company Sabre for $280 million in cash, the companies said in a statement on Friday, as consolidation in the online booking industry continues.

The deal follows a 2013 marketing agreement in which Expedia’s technology powered platforms for Travelocity’s U.S. and Canadian websites, while Travelocity drove additional web traffic to Expedia.

The merger marks further consolidation in the online booking space, which has seen a number of acquisitions from Expedia’s main competitor, The Priceline Group, including its $2.6 billion takeover of restaurant reservation website OpenTable last year.
“Given the success that they’ve had with integrating Travelocity into Brand Expedia (through the 2013 agreement), it’s a positive outcome,” said S&P Capital IQ analyst Tuna Amobi.

Expedia, which owns brands ranging from the website that carries its name to Hotels.com and China’s eLong, said in its October quarterly filing that its air ticket volumes grew 29 percent for the first three quarters of 2014, “primarily due to volume driven by Brand Expedia’s agreement with Travelocity along with ongoing improvements for the Brand Expedia sites themselves.”

“Evolving this relationship strengthens the Expedia family’s ability to continue to innovate and deliver the very best travel experiences to the widest set of travelers, all over the world,” Expedia’s Chief Executive Officer Dara Khosrowshahi said in Friday’s news release.

Travelocity is likely to maintain its unique brand within the umbrella of Expedia Inc, according to Amobi.

Sabre’s Chief Executive Officer Tom Klein said the company’s primary focus remains to be the providing of “mission-critical software solutions” to its global travel customers.

“We have had a long and fruitful partnership with Expedia, most recently by partnering to strengthen the Travelocity business, so our decision to divest Travelocity is a logical next step for us both,” he said in the statement.

Expedia’s shares rose 3.14 percent Friday to trade at $88.40, while Sabre’s shares gained 1.81 percent to trade at $20.85.

(By Jeffrey Dastin in New York; Editing by Alan Crosby)

This article originally appeared on Recode.net.

See More:

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh